Clik here to view.
Synthetic Bio Startup Senti Raises $53M to Program Cells to Treat Disease
Getting software to perform a new task is a matter of rewriting its code. This approach can also apply to biology, according to Tim Lu, CEO of Senti Biosciences. Tweaking a cell’s genetic code can...
View ArticleClik here to view.
Diagnostics Developer Nanopore Wins Agtech and Food Startup Showcase
In both humans and farm animals, time is crucial when diagnosing illness. An early diagnosis means treatment can be given before the disease worsens. In some forms of aquaculture, the diagnostic time...
View ArticleClik here to view.
Synthorx Raises $63M to Advance Suite of Enhanced Cytokine Drugs
After demonstrating in 2016 how its synthetic biology technology could produce new biologic drugs, San Diego’s Synthorx today revealed that its lead drug candidate is an improved version of...
View ArticleClik here to view.
Catalog Hauls In $9M to Make DNA-Based Data Storage Commercially Viable
The practice of encoding data in DNA molecules could be inching closer to graduating from research labs to finding practical commercial use.In the coming years, the explosion of data being generated by...
View ArticleClik here to view.
Precision Tinkering of Cells, Genes & Microbes: The Big Idea Finalists
Biology research has gotten so precise these days that scientists barely bat an eye when they talk about their ability to study the genome of individual cells or swap out single “letters” in DNA. So...
View ArticleClik here to view.
With Cronos Deal, Ginkgo Brings Synthetic Bio Approach to Cannabis
In a partnership that gives new meaning to mixing pot and beer, Canadian cannabis company Cronos Group has teamed with synthetic biology firm Ginkgo Bioworks to try and develop better ways of producing...
View ArticleClik here to view.
Xconomy’s San Francisco Event to Showcase Biotech’s Next Generation
The life sciences and biomedicine are a constant field of tension between cutting-edge ideas and breakthroughs, and time-tested procedures and regulations guided by experience and concerns for...
View ArticleClik here to view.
Pivot Bio Gets $70M, Led by Bill Gates’s Fund, to Replace Fertilizer
Applying fertilizers to fields has been a standard farming practice for generations. The problem with these chemicals is that they end up in the air or in water runoff. Scientists at agriculture...
View ArticleClik here to view.
Guardant Health’s IPO Tops Range, Raising $238M for Cancer Tests
Guardant Health continued the rapid drumbeat of life science IPOs this year by raising $237.5 million in its stock market debut, making it one of the biggest IPOs so far this year.The cancer...
View ArticleClik here to view.
Twist Bioscience IPO Hauls In $70M for DNA Synthesis Technology
Synthetic biology company Twist Bioscience has joined the long list of life science firms going public this year, raising $70 million in its stock market debut.The San Francisco company sold 5 million...
View ArticleClik here to view.
Synthorx Gets $131M in Upsized IPO for Synthetic Biology Drugs
Synthorx, which is working to develop cancer and autoimmune therapies using technology that allows it to expand the genetic alphabet, raised $131 million in an upsized IPO on Thursday.The company sold...
View ArticleClik here to view.
Ginkgo’s Motif Launches with $90M for Animal-Free Meat & Milk Proteins
[Updated 6:16 p.m. See below.] Plant-based foods and beverages are getting more grocery store shelf space as consumers increasingly shop for meat and milk alternatives. But these products typically...
View ArticleClik here to view.
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
Generic drugs are supposed to give consumers more choices and a counterweight to more costly branded medications. During his tenure as FDA commissioner, Scott Gottlieb often spoke about generics as a...
View ArticleClik here to view.
Motif Unveils New Name and $27.5M to Build Food Ingredients Pipeline
Plant-based meats and milks still use proteins, just not proteins that come from animals. Motif Ingredients has raised $27.5 million to build a pipeline of these animal-free protein ingredients.In...
View ArticleClik here to view.
Meissa Scores $30M to Test Vaccine for Dangerous Respiratory Virus
No vaccine is yet available for respiratory syncytial virus (RSV), which causes lung infections that, while usually mild, can be deadly for very young children. Biotech startup Meissa Vaccines, which...
View ArticleClik here to view.
Five Years After Y Combinator First Admits Biotechs, They’re Dug In
Five years ago, the big tech incubator Y Combinator started to welcome life sciences companies into its sizable startup classes, which had previously nurtured entrepreneurs in information technology...
View ArticleClik here to view.
ArsenalBio Launches With $85M for “Programmable” T Cell Therapies
Cell therapies are made by tinkering with a patient’s immune cells so that they can better recognize and destroy cancer cells. These drugs give patients another treatment option for certain cancers...
View ArticleClik here to view.
No More Fish or Fruit: Intrexon Turns SynBio Focus to Human Health
Intrexon has spent two decades designing and building DNA sequences for applications in healthcare, food, energy, and the environment. Going forward, the synthetic biology company will focus...
View ArticleClik here to view.
With $30M, Octant Launches Synthetic Bio Search for Multi-Target Drugs
Octant, a new drug discovery company, launched Wednesday with millions in backing from tech investors to push ahead plans to leverage advances in science and in tech—including genomics, synthetic...
View ArticleClik here to view.
Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More
The biggest life sciences deal this week involves a company that doesn’t discover or develop drugs, or even sell them. Yet its mark is found on pharmaceutical products spanning the entire...
View Article
